Open AccessSecond-line treatment with axitinib plus toripalimab in metastatic renal cell carcinoma: a retrospective multicenter study
Author(s) -
Jiwei Huang,
Guohai Shi,
Yueming Wang,
Ping Wang,
Jin Zhang,
Wen Kong,
Yiran Huang,
Shuo Wang,
Wei Xue
Publication year - 2022
Publication title -
future oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.857
H-Index - 72
eISSN - 1744-8301
pISSN - 1479-6694
DOI - 10.2217/fon-2021-1267
Subject(s) - axitinib , medicine , renal cell carcinoma , tyrosine kinase inhibitor , oncology , adverse effect , kidney cancer , urology , progression free survival , gastroenterology , cancer , chemotherapy , sunitinib
Aim: To evaluate the efficacy and safety of second-line treatment with axitinib plus toripalimab in patients with metastatic renal cell carcinoma and failure of VEGFR tyrosine kinase inhibitors. Methods: Data were collected restropectively. Kaplan–Meier analysis and Cox proportional hazards model determined the efficacy outcomes. Results: In 57 patients, objective response rate was 31.6% and median progression-free survival (PFS) was 11.7 months, while median overall survival was not reached. Median PFS was not reached in favorable-risk patients, whereas PFS of 11.0 and 7.8 months were observed in intermediate- and poor-risk patients, respectively (p = 0.011). The treatment-related toxicities were mild in nature. Conclusion: Second-line therapy with axitinib plus toripalimab provided durable response rate, longer PFS and a tolerable safety profile.